State Street
SLN icon

State Street’s Silence Therapeutics SLN Stock Holding History

State Street’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$238K Buy
+21,800
New +$265K ﹤0.01% 3858

Other funds holding SLN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $313B AUM 26.62% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return

State Street's SLN Position: Q3 2026 in Review

State Street opened a new position in Silence Therapeutics (SLN) in Q3 2026: 21,800 shares worth $238K. The stake represents ﹤0.01% of the portfolio and ranks #3858 among its holdings.

24 funds tracked by Wall St. Rank hold SLN as of Q3 2026.

  • State Street held 21,800 shares of Silence Therapeutics worth $238K as of Q3 2026.
  • Silence Therapeutics was a new State Street position in Q3 2026.
  • Silence Therapeutics made up ﹤0.01% of State Street's portfolio in Q3 2026, its #3858 holding.
  • 24 funds tracked by Wall St. Rank held Silence Therapeutics as of Q3 2026.

Based on State Street's 13F filing for Q3 2026, filed 12 Nov 2026.